Strides Arcolab Limited has got approval from the United States Food & Drug Administration (FDA) for lamivudine and zidovudine tablets USP, 150 mg/300 mg for HIV therapy.
The product will be manufactured at the company’s oral dosage facility at Bengaluru. The product will be launched in the US markets immediately
Lamivudine and zidovudine 150 mg/300 mg (generic version of Viiv's Combivir) belong to a class of antiviral medicines and is used with other antiretroviral medicines to treat HIV infection in adults and children. Lamivudine and zidovudine 150 mg/300 mg tablets reduces the amount of HIV in your body, and keeps it at a low level.
Subscribe to PharmaTutor News Alerts by Email >>
